P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
05 Jan 2020
Historique:
received: 14 09 2019
revised: 29 10 2019
accepted: 01 11 2019
pubmed: 24 11 2019
medline: 29 7 2020
entrez: 24 11 2019
Statut: ppublish

Résumé

Fisogatinib (BLU-554) is a highly selective and potent oral fibroblast growth factor receptor 4 (FGFR4) inhibitor currently in Phase I clinical trials for treatment of hepatocellular carcinoma (HCC). Using (male) genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, the OATP1A/1B uptake transporters, and the drug-metabolizing CYP3A complex in fisogatinib pharmacokinetics. In vitro, fisogatinib was modestly transported by hABCB1. Upon oral administration of 10 mg/kg fisogatinib, its brain accumulation was substantially increased in Abcb1a/1b

Identifiants

pubmed: 31759109
pii: S0378-5173(19)30887-7
doi: 10.1016/j.ijpharm.2019.118842
pii:
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B 0
Organic Cation Transport Proteins 0
Protein Kinase Inhibitors 0
Pyrans 0
Quinazolines 0
Recombinant Proteins 0
fisogatinib 5Q7R99CKV2
multidrug resistance protein 3 9EI49ZU76O
CYP3A protein, mouse EC 1.14.14.1
Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55
Fgfr4 protein, mouse EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 4 EC 2.7.10.1
Abcb1b protein, mouse EC 7.6.2.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118842

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Wenlong Li (W)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Rolf Sparidans (R)

Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands.

Mujtaba El-Lari (M)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Yaogeng Wang (Y)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Maria C Lebre (MC)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Jos H Beijnen (JH)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Alfred H Schinkel (AH)

Division of Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: a.schinkel@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH